您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定
收藏 | 浏览55

Fibroblast growth factor 21 (FGF21) shows great potential for the treatment of obesity and type 2 diabetes, as its long-acting analogue reduces body weight and improves lipid profiles of participants in clinical studies; however, the intracellular mechanisms mediating these effects are poorly understood. AMP-activated protein kinase (AMPK) is an important energy sensor of the cell and a molecular target for anti-diabetic medications. This work examined the role of AMPK in mediating the glucose and lipid-lowering effects of FGF21.Inducible adipocyte AMPK β1β2 knockout mice (iβ1β2AKO) and littermate controls were fed a high fat diet (HFD) and treated with native FGF21 or saline for two weeks. Additionally, HFD-fed mice with knock-in mutations on the AMPK phosphorylation sites of acetyl-CoA carboxylase (ACC)1 and ACC2 (DKI mice) along with wild-type (WT) controls received long-acting FGF21 for two weeks.Consistent with previous studies, FGF21 treatment significantly reduced body weight, adiposity, and liver lipids in HFD fed mice. To add, FGF21 improved circulating lipids, glycemic control, and insulin sensitivity. These effects were independent of adipocyte AMPK and were not associated with changes in browning of white (WAT) and brown adipose tissue (BAT). Lastly, we assessed whether FGF21 exerted its effects through the AMPK/ACC axis, which is critical in the therapeutic benefits of the anti-diabetic medication metformin. ACC DKI mice had improved glucose and insulin tolerance and a reduction in body weight, body fat and hepatic steatosis similar to WT mice in response to FGF21 administration.These data illustrate that the metabolic improvements upon FGF21 administration are independent of adipocyte AMPK, and do not require the inhibitory action of AMPK on ACC. This is in contrast to the anti-diabetic medication metformin and suggests that the treatment of obesity and diabetes with the combination of FGF21 and AMPK activators merits consideration.

作者:Emilio P, Mottillo;Eric M, Desjardins;Andreas M, Fritzen;Vito Z, Zou;Justin D, Crane;Julian M, Yabut;Bente, Kiens;Derek M, Erion;Adhiraj, Lanba;James G, Granneman;Saswata, Talukdar;Gregory R, Steinberg

来源:Molecular metabolism 2017 年 6卷 6期

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求,方便快速、便捷的获取实用的医学信息,辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明:本知识库提供的有关内容等信息仅供学习参考,不代替医生的诊断和医嘱。

收藏
| 浏览:55
作者:
Emilio P, Mottillo;Eric M, Desjardins;Andreas M, Fritzen;Vito Z, Zou;Justin D, Crane;Julian M, Yabut;Bente, Kiens;Derek M, Erion;Adhiraj, Lanba;James G, Granneman;Saswata, Talukdar;Gregory R, Steinberg
来源:
Molecular metabolism 2017 年 6卷 6期
标签:
ACC ACC DKI, ACC1-S79A and ACC2-S212A double knock-in ACC, acetyl-CoA carboxylase AKT, protein kinase B AMPK AMPK, AMP-activated protein kinase Adipocyte BAT, brown adipose tissue Brown fat CNS, central nervous system COX, cytochrome c oxidase CreERT2, Cre recombinase – estrogen receptor T2 DAG, diacylglycerol Diabetes FFA, free fatty acid FGF21 FGF21, fibroblast growth factor 21 FGFR1c, fibroblast growth factor receptor 1c GTT, glucose tolerance test H&E, hematoxylin and eosin HFD, high fat diet ITT, insulin tolerance test KLB, beta klotho NAFLD, non-alcoholic fatty liver disease Obesity RER, respiratory exchange ratio TAG, triacylglycerol UCP1, uncoupling protein 1 WAT, white adipose tissue WT, wildtype gWAT, gonadal white adipose tissue iWAT, inguinal white adipose tissue iβ1β2AKO, inducible AMPK β1β2 adipocyte knockout mTORC1, mammalian target of rapamycin
Fibroblast growth factor 21 (FGF21) shows great potential for the treatment of obesity and type 2 diabetes, as its long-acting analogue reduces body weight and improves lipid profiles of participants in clinical studies; however, the intracellular mechanisms mediating these effects are poorly understood. AMP-activated protein kinase (AMPK) is an important energy sensor of the cell and a molecular target for anti-diabetic medications. This work examined the role of AMPK in mediating the glucose and lipid-lowering effects of FGF21.Inducible adipocyte AMPK β1β2 knockout mice (iβ1β2AKO) and littermate controls were fed a high fat diet (HFD) and treated with native FGF21 or saline for two weeks. Additionally, HFD-fed mice with knock-in mutations on the AMPK phosphorylation sites of acetyl-CoA carboxylase (ACC)1 and ACC2 (DKI mice) along with wild-type (WT) controls received long-acting FGF21 for two weeks.Consistent with previous studies, FGF21 treatment significantly reduced body weight, adiposity, and liver lipids in HFD fed mice. To add, FGF21 improved circulating lipids, glycemic control, and insulin sensitivity. These effects were independent of adipocyte AMPK and were not associated with changes in browning of white (WAT) and brown adipose tissue (BAT). Lastly, we assessed whether FGF21 exerted its effects through the AMPK/ACC axis, which is critical in the therapeutic benefits of the anti-diabetic medication metformin. ACC DKI mice had improved glucose and insulin tolerance and a reduction in body weight, body fat and hepatic steatosis similar to WT mice in response to FGF21 administration.These data illustrate that the metabolic improvements upon FGF21 administration are independent of adipocyte AMPK, and do not require the inhibitory action of AMPK on ACC. This is in contrast to the anti-diabetic medication metformin and suggests that the treatment of obesity and diabetes with the combination of FGF21 and AMPK activators merits consideration.